Insulet Corp (PODD)
195.64
-1.08
(-0.55%)
USD |
NASDAQ |
Jul 05, 14:56
Insulet SG&A Expense (TTM): 771.90M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 771.90M |
December 31, 2023 | 734.90M |
September 30, 2023 | 666.40M |
June 30, 2023 | 626.10M |
March 31, 2023 | 621.80M |
December 31, 2022 | 587.80M |
September 30, 2022 | 565.20M |
June 30, 2022 | 542.30M |
March 31, 2022 | 484.20M |
December 31, 2021 | 466.00M |
September 30, 2021 | 474.40M |
June 30, 2021 | 446.10M |
March 31, 2021 | 410.60M |
December 31, 2020 | 384.00M |
September 30, 2020 | 334.40M |
June 30, 2020 | 320.00M |
March 31, 2020 | 315.00M |
December 31, 2019 | 298.00M |
September 30, 2019 | 278.24M |
June 30, 2019 | 276.21M |
March 31, 2019 | 259.35M |
December 31, 2018 | 248.00M |
September 30, 2018 | 247.55M |
June 30, 2018 | 226.22M |
March 31, 2018 | 217.24M |
Date | Value |
---|---|
December 31, 2017 | 208.90M |
September 30, 2017 | 197.65M |
June 30, 2017 | 185.70M |
March 31, 2017 | 174.52M |
December 31, 2016 | 166.08M |
September 30, 2016 | 158.75M |
June 30, 2016 | 155.60M |
March 31, 2016 | 149.31M |
December 31, 2015 | 138.80M |
September 30, 2015 | 109.14M |
June 30, 2015 | 106.57M |
March 31, 2015 | 108.44M |
December 31, 2014 | 108.10M |
September 30, 2014 | 122.43M |
June 30, 2014 | 127.61M |
March 31, 2014 | 120.72M |
December 31, 2013 | 119.77M |
September 30, 2013 | 118.94M |
June 30, 2013 | 106.31M |
March 31, 2013 | 105.15M |
December 31, 2012 | 103.95M |
September 30, 2012 | 103.18M |
June 30, 2012 | 100.57M |
March 31, 2012 | 96.86M |
December 31, 2011 | 87.32M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
278.24M
Minimum
Sep 2019
771.90M
Maximum
Mar 2024
490.91M
Average
474.40M
Median
Sep 2021
SG&A Expense (TTM) Benchmarks
Abbott Laboratories | 11.15B |
ResMed Inc | 915.63M |
Tandem Diabetes Care Inc | 352.80M |
Integra Lifesciences Holdings Corp | 655.78M |
OraSure Technologies Inc | 84.74M |